SEM (SEM)

Select Medical Holdings Corporation generated €4.64 billion in revenue last year, with its Critical Illness Recovery Hospital segment being the top performer, contributing €2.11 billion. The United States was the primary regional contributor, accounting for all of the company's revenue.

This article provides an overview of Select Medical (NYSE:SEM)'s SEC filings, highlighting that the company has submitted over 520 documents since 2017. It explains the importance of these filings for investors, detailing various form types such as 10-K, 10-Q, and 8-K. The most recent filing mentioned is a Form SCHEDULE 13G/A submitted on July 31, 2026.

Vanguard Portfolio Management LLC has filed an amended Schedule 13G, reporting beneficial ownership of 2,134 shares of Select Medical Holdings Corp common stock, which represents 0% of the outstanding class. The filing clarifies that Vanguard has sole dispositive power over these shares but no voting power. This disclosure includes holdings by Vanguard Portfolio Management LLC and its affiliates, indicating that no single person's interest constitutes more than 5% of the class.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 9.9% beneficial ownership stake in Select Medical Holdings Corp. (SEM). This translates to 12,320,106 shares, with BlackRock exercising sole voting power over 12,150,652 shares and sole dispositive power over all owned shares. The filing also notes that the iShares Core S&P Small-Cap ETF, an underlying fund, holds more than 5% of SEM's outstanding common stock.

SELECT MEDICAL HOLDINGS CORPORATION (SEM) disclosed $560,000 in lobbying expenditures for Q2 2026, focusing on regulations and Medicare payment issues related to long-term acute care hospitals and rehabilitation facilities. The article also highlights recent hedge fund activity in SEM stock, including significant adds and removals by institutional investors, and notes that two analysts have set a median price target of $16.5 for SEM.